×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Bellicum Pharmaceuticals Appoints New CEO During Dissolution - TipRanks.com
Tipranks
Bellicum Pharmaceuticals (BLCM) has released an update. Bellicum Pharmaceuticals, Inc. is undergoing a significant transformation as it...
2 months ago
Bellicum sells assets to MD Anderson, moves towards liquidation (OTCMKTS:BLCM)
Seeking Alpha
Bellicum Pharmaceuticals (BLCM) has completed the sale of substantially all of its assets to the MD Anderson Cancer Center and will proceed...
2 months ago
Bellicum Pharmaceuticals (OTCPK:BLCM) - Stock Price, News & Analysis
Simply Wall Street
BLCM Stock Overview. Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for...
11 months ago
Bellicum's GoCAR-Ts crash out of clinic over safety signal, sparking search for strategic alternatives
Fierce Biotech
Bellicum Pharmaceuticals' GoCAR-T cell therapies have skidded out, with the biotech halting trials of the two candidates over dose-limiting...
13 months ago
MD Anderson acquires inducible switch technologies for cell therapy
MD Anderson Cancer Center
MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms.
2 months ago
BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors
OncLive
Bellicum Pharmaceuticals has discontinued 2 phase 1/2 trials evaluating the safety and preliminary efficacy of the GoCAR T-cell products...
13 months ago
Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?
InvestorPlace
Bellicum Pharmaceuticals (BLCM) stock is rising higher on Monday morning following news of an investment in the company.
12 months ago
Trial failure causes Bellicum to view strategic alternatives
The Pharma Letter
Trial failure causes Bellicum to view strategic alternatives ... The trials for BPX-601 and BPX-603 are being discontinued following the company's...
13 months ago
Bellicum shares nose-dive on poor CAR-T data, program pause—company axes 79% of staffers
Fierce Biotech
Bellicum Pharmaceuticals' shares are being routed after it announced a full house of horrors: poor data, a paused program and slashing the...
42 months ago
Illumina names Hologic's MacMillan chair
BioCentury
Illumina Inc. (NASDAQ:ILMN) appointed Stephen MacMillan as chair, succeeding John Thompson who failed to win re-election at the company's...
11 months ago